中药治疗特发性肺纤维化急性加重患者的疗效与安全性:随机对照探索性临床试验的研究方案
本研究为随机、双盲、安慰剂对照的探索性临床试验,计划纳入80例特发性肺纤维化急性加重(AE-IPF)患者,在常规治疗基础上分别给予抗纤还肌颗粒或安慰剂颗粒,每次10克、每日两次,治疗4周后随访12周,主要结局为治疗失败率和全因死亡率。
要点
- 抗纤还肌颗粒每次10克、每日两次,联合常规治疗用于AE-IPF患者。
- 主要结局为治疗失败率和全因死亡率,随访至治疗后12周。
- 这是首个探索中药治疗AE-IPF疗效与安全性的临床试验。
核心结论
- 中药可能对特发性肺纤维化有益,但尚未在AE-IPF患者中评估,该试验首次探索中药治疗AE-IPF的疗效与安全性,结果将为进一步研究提供依据。
研究设计与样本
- 随机、双盲、安慰剂对照、探索性临床试验,计划纳入80例诊断为AE-IPF的患者,随机分为干预组或对照组。
- 干预组在常规治疗基础上给予抗纤还肌颗粒,对照组给予安慰剂颗粒,每次10克、每日两次,治疗4周后随访12周。
主要发现
- 主要结局为治疗失败率和全因死亡率。
- 次要结局包括住院时长、总生存期、急性加重率、插管率、改良英国医学研究委员会(mMRC)评分、圣乔治呼吸问卷特发性肺纤维化版(SGRQ-I)评分及动脉血气分析。
关键数值与推荐
- 抗纤还肌颗粒每次10克、每日两次,治疗4周后随访12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At present, there is short of effective treatment for acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). The treatment of IPF with traditional Chinese medicine (TCM) has some advantages. However, the evidence is unclear whether TCM can be recommended as an effective therapy to treat AE-IPF. The purpose of the study is to explore the efficacy and safety of TCM for patients with AE-IPF. METHODS: A randomized, double-blind, placebo-controlled, exploratory clinical trial will be performed. A total of 80 patients diagnosed with AE-IPF will be randomized into the intervention or control group. In addition to conventional treatment, the intervention group will be treated with Kangxianhuanji granule, and the control group will be given a placebo granule. The administration frequency is 10 g each time and two times daily. After 4 weeks of treatment, the patients were followed up for 12 weeks. The primary outcomes are treatment failure rate and all-cause mortality. Secondary outcome measures will include the length of hospitalization, overall survival, acute exacerbation rate, intubation rate, Modified British Medical Research Council (mMRC) score, the St George's Respiratory Questionnaire idiopathic pulmonary fibrosis (SGRQ-I) score, and arterial blood gas analysis. DISCUSSION: TCM may be beneficial in IPF. However, it has never been evaluated in patients with AE-IPF, who are incredibly prone to respiratory failure and have a high mortality rate. It is the first clinical trial to explore the efficacy and safety of TCM in the treatment of AE-IPF. This result will provide a basis for further study, which provides a high-quality evidence for the treatment of AE-IPF with TCM. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900026289 . Registered on 29 September 2019.
引用
- Hailong Z, Jiansheng L, Wen G, et al. Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial. Trials. 2022. PMID: 35109889. doi:10.1186/s13063-022-06026-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。